Sep 2021
DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).
These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.
A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.
AstraZeneca and Tesaro.
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Artios Pharma Ltd.
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
AstraZeneca.
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Duration MIN
Downloadable resources Yes
DOWNLOAD DDR BLUEPRINT
DOWNLOAD PARPi BLUEPRINT
Language(s)
Video
Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer
Downloadable 
5 MIN
Jul 2024 
Interactive patient case
Maximising outcomes for patients with advanced RCC
15 MIN
Jun 2024 
Other
Medical experts make recommendations for best practice
Downloadable
5 MIN
Jun 2024
Conference update
The latest non-small cell lung cancer data presented at ASCO
Downloadable
3 MIN
Jun 2024 
Conference update
GI oncologists review the latest data presented at ASCO 2024
8 MIN
Jun 2024 
Medical experts discuss the latest learnings from clinical practice
Downloadable
76 MIN
Jun 2024 
